Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 2Glioblastoma 2Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 94Radiotherapy 40Bevacizumab 40Lomustine 21Radiation 18Surgical Procedures, Operative 10Carboplatin 9pembrolizumab 8Nivolumab 8Carmustine 8Irinotecan 7IL13-PE38 6Granulocyte-Macrophage Colony-Stimulating Factor 6Flucytosine 6Cyclophosphamide 6ABT-414 6vocimagene amiretrorepvec 5depatuxizumab mafodotin 5Valacyclovir 5Drug Therapy 5veledimex 4sargramostim 4enzastaurin 4NVP-BKM120 4Gemcitabine 4Dianhydrogalactitol 4Chlorotoxin 4Aminolevulinic Acid 4verubulin 3selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Glioblastoma × CT-322 × Clear all
NCT00562419 2010-10-27

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 2 Unknown
72 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

NCT00768911 2010-10-27

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 1 Unknown
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡